---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-003149"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2022-01-06T23:59:59+00:00"
generated_at: "2026-06-27T20:15:57.670423+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zai Lab's NDA for margetuximab accepted by China NMPA for HER2+ breast cancer

## Summary
- NMPA accepted NDA for margetuximab, a HER2-targeted monoclonal antibody, for metastatic HER2+ breast cancer with 2+ prior anti-HER2 therapies.
- Margetuximab is the only HER2-targeted agent to show PFS improvement vs trastuzumab in head-to-head Phase 3 SOPHIA trial.
- NDA acceptance marks Zai Lab's sixth NDA acceptance by NMPA and expands women's oncology franchise.
- Bridging study in Chinese patients met primary endpoint of PFS by BICR; safety consistent with SOPHIA.

## SEC filing metadata
- accession: 0001193125-22-003149
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2022-01-06T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000119312522003149/0001193125-22-003149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000119312522003149/d274826d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-003149
- JSON: https://secwatch.observer/filing/0001193125-22-003149.json
- Plain text: https://secwatch.observer/filing/0001193125-22-003149.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.